Literature DB >> 3346545

Subcutaneous and intestinal vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to peroral and congenital toxoplasma challenge.

R McLeod1, J K Frenkel, R G Estes, D G Mack, P B Eisenhauer, G Gibori.   

Abstract

Mice were immunized s.c. or intraintestinally with two injections of a temperature-sensitive mutant of Toxoplasma gondii (ts4). Nonpersistence of the vaccine strain was documented by subinoculation of tissues of a subgroup of mice 3 mo or more after the second immunization. Mice were immune to other-wise lethal parenteral challenges with tachyzoites of the M7741 strain or to peroral challenge with bradyzoites of the Me49 strain of T. gondii. Although two s.c. or intraintestinal immunizations did not completely protect against development of T. gondii in the brains of mice, fewer cysts developed in the s.c. immunized mice than in control mice (2 +/- 3 cysts/0.01 ml in immunized mice compared with 75 +/- 48 cysts/0.01 ml in controls (p less than 0.002)). Reduction in cyst number after intraintestinal immunization was more variable, but also statistically significant (p less than 0.02). Female mice were first immunized, then mated, and then challenged perorally. Neonates of the s.c. immunized mice were not protected. Neonates of intraintestinally immunized mice were protected in part (36% of 115) against congenital infection compared with controls (7% of 107).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346545

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

Review 2.  Sexual recombination punctuated by outbreaks and clonal expansions predicts Toxoplasma gondii population genetics.

Authors:  Michael E Grigg; Natarajan Sundar
Journal:  Int J Parasitol       Date:  2009-02-13       Impact factor: 3.981

3.  Seroprevalence, isolation, molecular detection and genetic diversity of Toxoplasma gondii from small ruminants in Egypt.

Authors:  Khaled A Abd El-Razik; Ashraf M A Barakat; Hany A Hussein; Abdelgayed M Younes; Hassan A Elfadaly; Hazem A Eldebaky; Yousef A Soliman
Journal:  J Parasit Dis       Date:  2018-10-15

Review 4.  Toxoplasma gondii: 25 years and 25 major advances for the field.

Authors:  John C Boothroyd
Journal:  Int J Parasitol       Date:  2009-07-01       Impact factor: 3.981

5.  Antibody responses to Toxoplasma gondii in sera, intestinal secretions, and milk from orally infected mice and characterization of target antigens.

Authors:  T Chardès; I Bourguin; M N Mevelec; J F Dubremetz; D Bout
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

6.  Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.

Authors:  Kamal El Bissati; Aziz A Chentoufi; Paulette A Krishack; Ying Zhou; Stuart Woods; Jitender P Dubey; Lo Vang; Joseph Lykins; Kate E Broderick; Ernest Mui; Yasuhiro Suzuki; Qila Sa; Stephanie Bi; Nestor Cardona; Shiv K Verma; Laura Fraczek; Catherine A Reardon; John Sidney; Jeff Alexander; Alessandro Sette; Tom Vedvick; Chris Fox; Jeffrey A Guderian; Steven Reed; Craig W Roberts; Rima McLeod
Journal:  JCI Insight       Date:  2016-09-22

7.  T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest.

Authors:  Samuel L Hutson; Ernest Mui; Karen Kinsley; William H Witola; Michael S Behnke; Kamal El Bissati; Stephen P Muench; Brittany Rohrman; Susan R Liu; Robert Wollmann; Yuko Ogata; Ali Sarkeshik; John R Yates; Rima McLeod
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

8.  Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii.

Authors:  Hua Cong; Ernest J Mui; William H Witola; John Sidney; Jeff Alexander; Alessandro Sette; Ajesh Maewal; Rima McLeod
Journal:  Immunome Res       Date:  2010-12-03

9.  The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice.

Authors:  Mona M El Temsahy; Eman D H El Kerdany; Maha M Eissa; Thanaa I Shalaby; Iman M Talaat; Nermine M F H Mogahed
Journal:  J Parasit Dis       Date:  2014-09-05

10.  Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice.

Authors:  Valerie Letscher-Bru; Alexander W Pfaff; Ahmed Abou-Bacar; Denis Filisetti; Elisabeth Antoni; Odile Villard; Jean-Paul Klein; Ermanno Candolfi
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.